Combining Cyclosporine A and Steroids into a Single Hybrid Drug

A chemical method for linking cyclosporine A and steroid molecules into a single hybrid drug designed to treat eye conditions by releasing both components upon contact.

What it covers

This patent describes a molecular hybrid that physically links a cyclosporine A molecule to a steroid molecule using a chemical bridge called a linker. The goal is to create a single drug entity that can be applied topically to the eye. Once applied, the body's natural enzymes or moisture cause the linker to break, releasing the two active drugs simultaneously to provide a combined therapeutic effect.

What it doesn't cover

• —Does not cover the individual use of cyclosporine A or steroids as separate, non-linked medications.
• —Does not cover any random combination of drugs that are not specifically linked via the described chemical structures.
• —Does not cover delivery systems that use physical mixtures of drugs rather than a single covalently bonded molecule.

The clever bit

The innovation lies in the specific chemical linker design that remains stable during storage but reliably cleaves upon exposure to the unique enzymatic environment of the eye.

Why it matters

This approach attempts to simplify complex treatment regimens for chronic eye conditions, such as dry eye or inflammation, by combining two potent drugs into one application. By creating a single hybrid molecule, researchers aim to improve patient compliance and potentially enhance the delivery efficiency of both drugs to the target tissue.

Real-world examples

• 1.Experimental hybrid drug formulations for ocular inflammation
• 2.Topical eye drop candidates for chronic dry eye disease